In the dynamic field of life sciences, nanobody—or Variable Heavy-chain Domain (VHH)—is emerging as a powerful tool for researchers. Derived from the immune systems of camelid species like llamas and alpacas, this small, single-domain antibody offers unique advantages over traditional antibodies.
|
Nanobody drug |
Target |
Indication |
Clinical trial identifier |
Highest phase |
Sponsor |
|
Caplacizumab |
A1-domain of VWF |
Thrombotic thrombocytopenic
purpura |
FDA/EMA approved |
FDA/EMA approved |
Ablynx |
|
ALX-148 |
CD47 |
Solid tumors and lymphoma |
NCT03013218 |
I |
ALX Oncology Inc. |
|
ALX-0171 |
RSV |
RSV lower respiratory tract
infection |
NCT02979431 |
II |
Ablynx |
|
Vobarilizumab |
IL-6R |
Rheumatoid arthritis |
NCT02287922 |
II |
Ablynx |
|
Vobarilizumab |
IL-6R |
Systemic lupus erythematosus |
NCT02437890 |
II |
Ablynx |
|
Ozoralizumab |
TNF |
Rheumatoid arthritis |
NCT04077567 |
III |
Taisho Pharmaceutical Co., Ltd. |
|
M1095 |
IL 17A, IL 17F and IL 17A/F |
Psoriasis |
NCT03384745 |
II |
Bond and Avillion 2 Development LP |
|
MSB0010841 |
IL 17-A/F |
Psoriasis |
NCT02156466 |
I |
Merck KGaA |
|
VHH batch 203027 |
Rotavirus |
Rotaviral diarrhea |
NCT01259765 |
II |
International Centre for
Diarrhoeal Disease Research |
|
ARP1 |
Rotavirus |
Rotavirus gastroenteritis |
NCT01265355 |
II/III |
Christian Medical College |
|
M6495 |
ADAMTS-5 |
Osteoarthritis |
NCT03583346 |
I |
Merck KGaA |
|
BI 836880 |
VEGF |
Oncology |
NCT02689505 |
I |
Boehringer Ingelheim |
|
BI 655088 |
CX3CR1 |
Chronic kidney disease |
NCT02696616 |
I |
Boehringer Ingelheim |
|
KN035 |
PD-L1 |
Multiple primary neoplasm |
NCT04182789 |
II |
Ren Ji Hospital |
|
KN044 |
CTLA-4 |
Advanced solid tumors |
NCT04126590 |
I |
Changchun IntelliCrown
Pharmaceutical Co. LTD |
|
CD19/CD20 bispecific CAR T cells |
CD19/CD20 |
Refractory/Relapsed B-cell
lymphoma stage |
NCT03881761 |
I |
Henan Cancer Hospital |
|
BCMA CAR T cells |
BCMA |
Refractory/Relapsed myeloma |
NCT03664661 |
I |
Henan Cancer Hospital |
|
L-DOS47+doxorubicin |
CEA CAM6 |
Pancreas cancer |
NCT04203641 |
I/II |
Helix BioPharma Corporation |
|
L-DOS47+cisplatin/vinorelbine |
CEA CAM6 |
Lung adenocarcinoma |
NCT03891173 |
II |
Helix BioPharma Corporation |
|
KN035+trastuzumab/docetaxel |
PD-L1 |
Breast Cancer |
NCT04034823 |
II |
Sun Yat-Sen Memorial Hospital |
|
LCAR-B38M |
BCMA |
Multiple myeloma |
NCT03758417 |
II |
Nanjing Legend Biotech Co. |
Why Choose Our Nanobody Products?
At Echo Bio, we provide high-quality nanobody products tailored for life science research, including:
- Custom Development: Tailored nanobody specific to your research needs.
- Ready-to-Use Options: A catalog of pre-validated nanobody for various applications.
- Expert Support: Our team is here to help you maximize the potential of our products.
